DarioHealth Corp.

NASDAQ:DRIO

Medical - Diagnostics & Research

Healthcare
$5.13 -1.68%

-$0.12 today

Market cap
$50.27M
Beta
1.08
P/E (TTM)
5.5
EPS (TTM)
$1.26
52W Low $5.94High $17.74

Volume 0.01M

Average 0.01M

DRIO Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

DarioHealth Corp.NASDAQ: DRIO

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables turns positive

Q1 FY2026 accounts payables was $535K, compared with -$300K a year earlier. Trailing-twelve-month accounts payables was $713K. Over 3 fiscal years it compounded at -64.8% a year.

Context

  • Accounts payables amounted to 0.5% of revenue in FY2025, down 1.3 pp from a year earlier.
  • Accounts payables grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near $535K or moves back toward the trailing-twelve-month quarterly average of $178.25K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$535K+198.0% QoQ
Last fiscal yearDec 2025
-$122K-75.4% YoY
LTMMar 2026
$713K+147.4% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+278.3%——
1 year-75.4%——
3-year CAGR-64.8%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(122K) USD
Year-over-year change
+75.4%

Accounts Payables vs competitors

How DRIO compares with its peers on the latest reported figures

  • DRIO's LTM Mar 2026 accounts payables of $713K is the 10th largest of the 11 companies compared; the peer median is $1.26M.
  • Its year-over-year change of +147.4% is the 6th highest of 11, against a peer median of +132.4%.
  • Accounts payables amounts to 3.4% of revenue for DRIO, versus a peer median of 2.1%.
DRIO Competitors Peer median
Accounts Payables for DRIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INNVInnovAge Holding Corp.LTM Mar 2026$40.68M +418.2%—4.3%
OFIXOrthofix Medical Inc.LTM Mar 2026$19.16M +164.5%+4.4%2.3%
AVNSAvanos Medical, Inc.LTM Mar 2026$4.9M +151.0%-74.3%0.7%
MYGNMyriad Genetics, Inc.LTM Mar 2026$4M +385.7%-26.3%0.5%
VSTMVerastem, Inc.LTM Mar 2026$2.4M +1061.2%+48.0%4.8%
ABSIAbsci CorporationLTM Mar 2026$2.17M -170.0%—118.3%
RGNXREGENXBIO Inc.LTM Mar 2026$1.72M +113.8%—2.0%
NNNNAnbio Biotechnology Class A Ordinary SharesFY2025$1.63M -303.6%+50.0%16.7%
FLGTFulgent Genetics, Inc.LTM Mar 2026$800K -69.8%—0.2%
DRIODarioHealth Corp.LTM Mar 2026$713K +147.4%-64.8%3.4%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$315K -95.3%+34.3%0.2%
Peer median (excluding DRIO) $1.26M+132.4%+19.4%2.1%

Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(76.76M)(62.19M)(59.43M)(42.75M)(41.71M)
Depreciation & Amortization4.46M4.72M4.99M7.43M2.83M
Deferred Income Tax00000
Stock-Based Compensation24.97M16.98M19.7M15.8M9.37M
Change in Working Capital(2.57M)(10.9M)4.07M(2.47M)2.21M
Accounts Receivables(367K)(5.11M)2.84M1.6M2.64M
Inventory(2.23M)(1.73M)2.89M308K437K
Accounts Payables1.08M(2.79M)(1.19M)(496K)(122K)
Other Working Capital(1.06M)(1.28M)(464K)(3.88M)(752K)
Other Non-Cash Items(503K)3.56M288K(16.57M)1.37M
Operating Cash Flow(50.41M)(47.85M)(30.38M)(38.56M)(25.94M)
Capital Expenditures(261K)(573K)(584K)(138K)(142K)
Acquisitions (Net)(7.47M)00(8.8M)0
Purchases of Investments00(5M)0(4.2M)
Sales of Investments005.03M00
Other Investing Activities(400K)(131K)000
Investing Cash Flow(8.13M)(573K)(547K)(8.93M)(4.34M)
Debt Repayment023.79M1.77M0185K
Common Stock Issued64.88M38.29M1.61M024.13M
Common Stock Repurchased0(134K)000
Dividends Paid00000
Other Financing Activities889K0000
Financing Cash Flow65.77M61.94M18.25M38.53M24.31M
Effect of Forex Changes000(68K)9K
Net Change in Cash7.22M13.52M(12.67M)(9.03M)(5.96M)
Free Cash Flow(50.67M)(48.42M)(30.96M)(38.7M)(26.08M)

DarioHealth Corp.

NASDAQ:DRIO

Intrinsic Alpha fair value

Locked

Current Price

$5.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.